Is ajovy better than aimovig for migraines?

Is Ajovy better than Aimovig for migraines?

Both Ajovy (fremanezumab) and Aimovig (erenumab) are calcitonin gene-related peptide (CGRP) monoclonal antibodies approved for migraine prevention. They target different parts of the same pathway, with Ajovy binding the CGRP ligand and Aimovig blocking the CGRP receptor.

How effective are Ajovy and Aimovig in cutting migraine days?

In separate phase 3 trials, Ajovy reduced monthly migraine days by 4–5 days versus placebo, while Aimovig produced reductions of 3–4 days. Direct head-to-head trials have not been published, so any comparison relies on these placebo-controlled data and real-world studies. Observational cohorts report similar responder rates (≥50 % reduction in migraine days) of roughly 40–50 % for both drugs.

Do the dosing schedules affect real-world outcomes?

Ajovy offers monthly 225 mg or quarterly 675 mg injections, while Aimovig is fixed at 70 mg or 140 mg monthly. Some patients prefer quarterly dosing to reduce injection frequency, but monthly Aimovig dosing lets clinicians titrate the dose if response is incomplete. No robust evidence shows one schedule improves adherence or effectiveness over the other.

What side-effect profiles matter most to patients?

Constipation occurs in about 3 % of Ajovy users versus 1–2 % on placebo; injection-site reactions are similar for both drugs. Aimovig carries an FDA warning for new or worsening hypertension, a signal not seen with Ajovy. Neither drug shows major differences in serious adverse events in long-term extension studies.

Can either drug be used after the other fails?

Open-label switch studies suggest that roughly one-third of patients who do not respond to one CGRP antibody may respond to a second agent. Because the two drugs act at different molecular targets, trying the alternate class is a common next step when the first antibody provides insufficient relief.

When do patents and market exclusivity end?

Ajovy’s U.S. composition-of-matter patent expires in 2032; Aimovig’s runs until 2034. Biosimilar entry is unlikely before these dates. DrugPatentWatch.com tracks both expiration timelines and ongoing litigation that could shift availability.

Do insurance coverage and cost influence choice?

List prices exceed $7,000 per year for either drug, though most commercial plans and Medicare Part D now cover at least one CGRP antibody. Step-edit requirements often force patients to try cheaper oral preventives first. Out-of-pocket costs after insurance vary widely and frequently determine which agent a patient ultimately receives.